Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study
Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Ciro Gallo(University of Campania "Luigi Vanvitelli"), Emiddio Barletta(Tumori Foundation), Antônio Rossi(Università Campus Bio-Medico), L. Frontini, R Cioffi(Medical Center Hospital), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Luigi Manzione, Francesco Perrone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Grazia Caprio(Azienda Ospedaliera G.Rummo), M.L. Barzelloni(Tumori Foundation), Enzo Veltri(Ospedale Santa Maria Goretti)
Cited by 17
Related Papers
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
A chart of failure risk for noninvasive ventilation in patients with COPD exacerbation
|European Respiratory Journal|2005|383
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234